keyword
MENU ▼
Read by QxMD icon Read
search

neoadjuvant chemoradiotherapy

keyword
https://www.readbyqxmd.com/read/29353163/time-interval-between-neoadjuvant-chemoradiotherapy-and-surgery-for-oesophageal-or-junctional-cancer-a-nationwide-study
#1
L R van der Werf, J L Dikken, E M van der Willik, M I van Berge Henegouwen, G A P Nieuwenhuijzen, B P L Wijnhoven
INTRODUCTION: The optimal time between end of neoadjuvant chemoradiotherapy (nCRT) and oesophagectomy is unknown. The aim of this study was to assess the association between this interval and pathologic complete response rate (pCR), morbidity and 30-day/in-hospital mortality. METHODS: Patients with oesophageal cancer treated with nCRT and surgery between 2011 and 2016 were selected from a national database: the Dutch Upper Gastrointestinal Cancer Audit (DUCA). The interval between end of nCRT and surgery was divided into six periods: 0-5 weeks (n = 157;A), 6-7 weeks (n = 878;B), 8-9 weeks (n = 972;C), 10-12 weeks (n = 720;D), 13-14 weeks (n = 195;E) and 15 or more weeks (n = 180;F)...
January 17, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29346536/residual-carcinoma-cells-after-chemoradiotherapy-for-esophageal-squamous-cell-carcinoma-patients-striving-toward-appropriate-judgment-of-biopsy
#2
F Fujishima, Y Taniyama, Y Nakamura, H Okamoto, Y Ozawa, K Ito, H Ishida, T Konno-Kumagai, A Kasajima, S Taniuchi, M Watanabe, T Kamei, H Sasano
In esophageal squamous cell carcinoma (ESCC) patients who are treated with chemoradiotherapy (CRT), identification of the presence or absence of residual or recurrent carcinoma is usually pivotal in their clinical management. In addition, the extent of carcinoma invasion into the esophageal wall could determine the clinical outcome of these patients following CRT. Therefore, in this study, we evaluated the response to CRT both macroscopically and histologically in a consecutive series of 42 ESCC patients receiving neoadjuvant chemoradiotherapy following curative esophageal resection at Tohoku University Hospital between August 2011 and December 2012...
January 13, 2018: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
https://www.readbyqxmd.com/read/29344808/minimally-invasive-esophagectomy-with-thoracic-duct-resection-post-neoadjuvant-chemoradiotherapy-for-carcinoma-esophagus-impact-on-lymph-node-yield-and-hemodynamic-parameters
#3
Santosh Anand, Raja Kalayarasan, Sandip Chandrasekar, Senthil Gnanasekaran, Biju Pottakkat
BACKGROUND: Neoadjuvant therapy followed by surgery is the current recommended treatment for locally advanced esophageal carcinoma. Thoracic duct (TD) resection was indicated for radical mediastinal lymphadenectomy. However, TD resection can cause hemodynamic disturbances. The presence of metastasis in TD has not been previously studied. METHODS: Twenty-two patients who underwent minimally invasive esophagectomy with D2 lymphadenectomy after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma were analyzed...
January 18, 2018: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/29341150/effect-of-akt-activation-and-experimental-pharmacological-inhibition-on-responses-to-neoadjuvant-chemoradiotherapy-in-rectal-cancer
#4
F C Koyama, C M Lopes Ramos, F Ledesma, V A F Alves, J M Fernandes, B B Vailati, G P São Julião, A Habr-Gama, J Gama-Rodrigues, R O Perez, A A Camargo
BACKGROUND: Neoadjuvant chemoradiotherapy (CRT) is one of the preferred initial treatment strategies for locally advanced rectal cancer. Responses are variable, and most patients still require surgery. The aim of this study was to identify molecular mechanisms determining poor response to CRT. METHODS: Global gene expression and pathway enrichment were assessed in pretreatment biopsies from patients with non-metastatic cT2-4 N0-2 rectal cancer within 7 cm of the anal verge...
January 2018: British Journal of Surgery
https://www.readbyqxmd.com/read/29340601/how-to-treat-borderline-resectable-pancreatic-cancer-current-challenges-and-future-directions
#5
Shinichiro Takahashi
Borderline resectable pancreatic cancer (BRPC) is an advanced tumor in contact with the surrounding major vessels, making R0 resection difficult to achieve. Neoadjuvant treatment is expected to provide substantial local control and prolong survival. However, there is no standard treatment. I therefore conducted a strategic literature search from January 2013 to September 2017 and identified 37 clinical studies of pancreatic cancer, including BRPC, to evaluate treatment interventions. Twenty (54%) studies were prospective...
January 11, 2018: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29339209/extratumoral-pd-1-blockade-does-not-perpetuate-obesity-associated-inflammation-in-esophageal-adenocarcinoma
#6
Karen C Galvin, Melissa J Conroy, Suzanne L Doyle, Margaret R Dunne, Ronan Fahey, Emma Foley, Katie E O'Sullivan, Derek G Doherty, Justin G Geoghegan, Narayanasamy Ravi, Cliona O'Farrelly, John V Reynolds, Joanne Lysaght
Checkpoint inhibitors, such as anti-PD-1 (Programmed death-1), are transforming cancer treatment for inoperable or advanced disease. As the incidence of obesity-associated malignancies, including esophageal adenocarcinoma (EAC) continue to increase and treatment with checkpoint inhibitors are being FDA approved for a broader range of cancers, it is important to assess how anti-PD-1 treatment might exacerbate pre-existing inflammatory processes at other sites. Outside the EAC tumor, the omentum and liver were found to be enriched with substantial populations of PD-1 expressing T cells...
January 12, 2018: Cancer Letters
https://www.readbyqxmd.com/read/29338734/comparing-the-benefits-of-chemoradiotherapy-and-chemotherapy-for-resectable-stage-iii-a-n2-non-small-cell-lung-cancer-a-meta-analysis
#7
REVIEW
Yuqiao Chen, Xiong Peng, Yuan Zhou, Kun Xia, Wei Zhuang
BACKGROUND: Induction chemotherapy has been shown to improve survival of patients with stage III A/N2 (T1-3, N2, M0) non-small cell lung cancer (NSCLC), followed by resection, but the benefits of neoadjuvant radiotherapy still remain controversial. METHODS: PubMed, Embase, and Cochrane library databases were searched for relevant randomized controlled trials (RCTs) comparing the outcomes of induction chemoradiotherapy over induction chemotherapy, in patients with resectable stage IIIA/N2 NSCLC...
January 16, 2018: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29334555/multi-institutional-analysis-of-recurrence-and-survival-after-neoadjuvant-chemoradiotherapy-of-esophageal-cancer-impact-of-histology-on-recurrence-patterns-and-outcomes
#8
Mian Xi, Yadi Yang, Li Zhang, Hong Yang, Kenneth W Merrell, Christopher L Hallemeier, Robert K Shen, Michael G Haddock, Wayne L Hofstetter, Dipen M Maru, Linus Ho, Carol C Wu, Mengzhong Liu, Steven H Lin
OBJECTIVE: To determine the impact of histology on pathologic response, survival outcomes, and recurrence patterns in patients with esophageal cancer (EC) who received neoadjuvant chemoradiotherapy (CRT). SUMMARY OF BACKGROUND DATA: There is a paucity of data regarding comparative outcomes after neoadjuvant CRT between esophageal squamous cell carcinoma (SCC) and adenocarcinoma. METHODS: Between 2002 and 2015, 895 EC patients who underwent neoadjuvant CRT followed by esophagectomy at 3 academic institutions were retrospectively reviewed, including 207 patients with SCC (23...
January 12, 2018: Annals of Surgery
https://www.readbyqxmd.com/read/29332233/pilot-study-of-serial-flt-and-fdg-pet-ct-imaging-to-monitor-response-to-neoadjuvant-chemoradiotherapy-of-esophageal-adenocarcinoma-correlation-with-histopathologic-response
#9
Victor H Gerbaudo, Joseph H Killoran, Chun K Kim, Jason L Hornick, Jonathan A Nowak, Peter C Enzinger, Harvey J Mamon
OBJECTIVE: The aim of this prospective pilot study was to investigate the potential of serial FLT-PET/CT compared to FDG-PET/CT to provide an early indication of esophageal cancer response to concurrent neoadjuvant chemoradiation therapy. METHODS: Five patients with biopsy-proven esophageal adenocarcinomas underwent neoadjuvant chemoradiation (Tx) prior to minimally invasive esophagectomy. The presence of residual tumor was classified histologically using the Mandard et al...
January 13, 2018: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/29331036/prognostic-significance-of-mir-21-and-pdcd4-in-patients-with-stage-ii-esophageal-carcinoma-after-surgical-resection
#10
Jiandong Zhang, Lei Ma, Daimeng Shi, Zhen Zhang, Chuanshan Yao, Xulin Zhao, Quanxiao Xu, Penghao Wen, Limin He
Many studies have shown that randomized clinical trial with long-term follow-up found no improvement in stage II esophageal carcinoma (EC) patients receiving preoperative neoadjuvant chemoradiotherapy or chemotherapy treatment, this limitation underscored the urgent need for novel and reliable biomarkers for prognosis and prediction in stage II EC. miR-21 is frequently over-expressed while programmed cell death 4 (PDCD4) is often down-regulated in solid tumors. This study aimed to investigate the clinicopathological and prognostic significance of miR-21 and PDCD4 expression and to elucidate any correlation between miR-21 and PDCD4 expression in stage II EC patients...
January 13, 2018: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/29329555/exercise-during-and-after-neoadjuvant-rectal-cancer-treatment-the-exert-trial-study-protocol-for-a-randomized-controlled-trial
#11
Andria R Morielli, Nawaid Usmani, Normand G Boulé, Diane Severin, Keith Tankel, Tirath Nijjar, Kurian Joseph, Alysa Fairchild, Kerry S Courneya
BACKGROUND: Standard treatment for locally advanced rectal cancer includes 5-6 weeks of neoadjuvant chemoradiotherapy (NACRT) followed by total mesorectal excision 6-8 weeks later. NACRT improves local disease control and surgical outcomes but also causes side effects including fatigue, diarrhea, hand-foot syndrome, and physical deconditioning that may impede quality of life (QoL), treatment completion, treatment response, and long-term prognosis. Interventions to improve treatment outcomes and manage side effects that are safe, tolerable and low-cost are highly desirable...
January 12, 2018: Trials
https://www.readbyqxmd.com/read/29323141/comparison-long-term-outcome-of-definitive-radiotherapy-plus-different-chemotherapy-schedules-in-patients-with-advanced-nasopharyngeal-carcinoma
#12
Yi-Chun Liu, Wen-Yi Wang, Chih-Wen Twu, Rong-San Jiang, Kai-Li Liang, Po-Ju Lin, Jing-Wei Lin, Jin-Ching Lin
Concurrent chemoradiotherapy (CCRT) is the current standard of care for advanced nasopharyngeal carcinoma (NPC). We hypothesize that shifting CCRT to neoadjuvant chemotherapy followed by radiotherapy (NeoCT-RT) is an alternative option. From December 2004 to January 2009, 256 NPC patients with stage II-IVB were treated by either CCRT or NeoCT-RT. All patients received the same dosage and fractionation schedule of RT. After long-term follow-up, 26.8% (34/127) and 23.3% (30/129) of patients who received CCRT and NeoCT-RT respectively, developed a tumor relapse (P = 0...
January 11, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29318432/the-price-study-the-role-of-conventional-and-diffusion-weighted-magnetic-resonance-imaging-in-assessment-of-locally-advanced-cervical-cancer-patients-administered-by-chemoradiation-followed-by-radical-surgery
#13
A L Valentini, M Miccò, B Gui, M Giuliani, E Rodolfino, A M Telesca, T Pasciuto, A Testa, M A Gambacorta, G Zannoni, V Rufini, A Giordano, V Valentini, G Scambia, R Manfredi
OBJECTIVES: To analyse the role of DW-MRI in early prediction of pathologically-assessed residual disease in locally-advanced cervical cancer (LACC) treated with neoadjuvant chemoradiotherapy followed by radical surgery. METHODS: Between October 2010-June 2014, 108 women with histologically-proven cervical cancer were screened; 88 were included in this study. Tumour volume (TV) and ADCmean were measured before (baseline-MRI) and after 2 weeks of chemoradiotherapy (early-MRI)...
January 9, 2018: European Radiology
https://www.readbyqxmd.com/read/29290268/recurrence-dynamics-after-trimodality-therapy-neoadjuvant-concurrent-chemoradiotherapy-and-surgery-in-patients-with-stage-iiia-n2-lung-cancer
#14
Junghee Lee, Hong Kwan Kim, Byung Jo Park, Jong Ho Cho, Yong Soo Choi, Jae Ill Zo, Young Mog Shim, Hongryull Pyo, Yong Chan Ahn, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Jhingook Kim
INTRODUCTION: We investigated the timing and patterns of recurrence after the treatment of stage IIIA (N2) non-small cell lung cancer via neoadjuvant concurrent chemoradiotherapy followed by surgery. MATERIALS AND METHODS: An institutional database was reviewed retrospectively between 1997 and 2013 (N=570). Eligible patients had pathologically proven N2 disease, and they completed the planned trimodality therapy with curative intent. The hazard rate function and competing risk analysis were used to evaluate the recurrence dynamics...
January 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29277386/outcomes-of-persistent-lymph-node-involvement-after-neoadjuvant-therapy-for-stage-iii-rectal-cancer
#15
Anne M Dinaux, Lieve Leijssen, Liliana G Bordeianou, Hiroko Kunitake, Ramzi Amri, David L Berger
INTRODUCTION: Lymph node involvement is a well-known predictor of recurrent rectal cancer in patient who did not undergo neoadjuvant therapy patients. The role of persistent lymph node disease after neoadjuvant treatment, however, is debatable. This study compares outcomes of patients with clinical, stage III rectal cancer who had nodal disease on surgical pathology after neoadjuvant treatment to patients with negative nodes. METHODS: We reviewed retrospectively a consecutive cohort of all clinical, American Joint Committee on Cancer stage III rectal cancer patients who received neoadjuvant chemoradiotherapy and had an R0 resection at the Massachusetts General Hospital between 2004 and 2015...
December 22, 2017: Surgery
https://www.readbyqxmd.com/read/29275912/advances-in-organ-preserving-strategies-in-rectal-cancer-patients
#16
REVIEW
Rutger C H Stijns, Mike-Stephen R Tromp, Niek Hugen, Johannes H W de Wilt
Treatment of rectal cancer patients has been subjected to change over the past thirty years. Total mesorectal excision is considered the cornerstone of rectal cancer treatment, but is also associated with significant morbidity resulting in an impaired quality of life. The addition of neoadjuvant chemoradiotherapy to surgery has shown to improve survival and local control and may lead to a partial or even complete response (CR). This raises questions regarding the necessity for subsequent radical surgery. After careful patient selection local excision and wait-and-see approaches are explored, aiming to improve quality of life without compromising oncological outcome...
December 12, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29273261/genotype-driven-phase-i-study-of-weekly-irinotecan-in-combination-with-capecitabine-based-neoadjuvant-chemoradiation-for-locally-advanced-rectal-cancer
#17
Ji Zhu, Xinxiang Li, Yunzhu Shen, Yun Guan, Weilie Gu, Peng Lian, Weiqi Sheng, Sanjun Cai, Zhen Zhang
PURPOSE: We aimed to identify the maximum tolerated dose (MTD) of weekly irinotecan in combination with capecitabine-based neoadjuvant chemoradiation according to the UGT1A1∗28 genotype in patients with locally advanced rectal cancer. PATIENTS AND METHODS: Patients with clinical stage T3-4, N0-2 who were eligible for preoperative chemoradiotherapy were screened for the UGT1A1∗28 genotype. Twenty-six patients with either the ∗1∗1 or ∗1∗28 genotype were eligible for dose escalation of irinotecan, and patients with a ∗28∗28 genotype were excluded...
December 19, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/29247263/pretreatment-identification-of-patients-likely-to-have-pathologic-complete-response-after-neoadjuvant-chemoradiotherapy-for-rectal-cancer
#18
Frederik J van der Sluis, Henderik L van Westreenen, Boudewijn van Etten, Barbara L van Leeuwen, Geertruida H de Bock
PURPOSE: In selected patients, a wait-and-see strategy after chemoradiotherapy for rectal cancer might be feasible provided that the probability of pathologic complete response (pCR) is high. This study aimed to identify clinical parameters associated with pCR. Furthermore, we attempted to identify subgroups with increased probability of pCR that might aid in clinical decision making. METHODS: A total of 6444 patients that underwent surgical resection of a single primary carcinoma of the rectum after neoadjuvant chemoradiotherapy (nCRT) between January 2009 and December 2016 in the Netherlands were included in the study...
December 15, 2017: International Journal of Colorectal Disease
https://www.readbyqxmd.com/read/29246020/neoadjuvant-chemotherapy-with-different-dose-regimens-of-docetaxel-cisplatin-and-fluorouracil-tpf-for-locoregionally-advanced-nasopharyngeal-carcinoma-a-retrospective-study
#19
Ting Jin, Qun Zhang, Feng Jiang, Wei-Feng Qin, Qi-Feng Jin, Cai-Neng Cao, Yong-Feng Piao, Xing-Lai Feng, Wei Luo, Xiao-Zhong Chen
Objective: Compare high- vs. low-dose TPF neoadjuvant chemotherapy with chemoradiotherapy in Chinese patients with locoregionally advanced nasopharyngeal carcinoma (NPC). Materials and Methods: Retrospective analysis of 210 stage III/IV NPC patients treated between April 1, 2012 and April 1, 2014; 138 received three cycles of high-dose TPF (H-TPF) every 3 weeks at Zhejiang Cancer Hospital and 72, three cycles of low-dose TPF (L-TPF) every 3 weeks at Sun Yat-Sen University Cancer Center...
November 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/29243205/correction-to-a-phase-ii-study-evaluating-combined-neoadjuvant-cetuximab-and-chemotherapy-followed-by-chemoradiotherapy-and-concomitant-cetuximab-in-locoregional-oesophageal-cancer-patients
#20
Maria Alsina, Fernando Rivera, Francisco Javier Ramos, Maica Galán, Rafael López, Pilar García-Alfonso, José Enrique Alés-Martinez, Bernardo Queralt, Antonio Antón, Alfredo Carrato, Cristina Grávalos, Maria José Méndez-Vidal, Carlos López, Inmaculada Ruiz de Mena, Josep Tabernero, Jordi Giralt, Enrique Aranda
Errors were subsequently identified in the article and the following corrections should be noted.
December 14, 2017: Targeted Oncology
keyword
keyword
31922
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"